Effect of Angiotensin II on ENaC in the Distal Convoluted Tubule and in the Cortical Collecting Duct of Mineralocorticoid Receptor Deficient Mice

Peng Wu, PhD; Zhong-Xiuzi Gao, MD; Dan-Dan Zhang, PhD; Xin-Peng Duan, PhD; Andrew S. Terker, MD; Dao-Hong Lin, MD, PhD; David H. Ellison, MD; Wen-Hui Wang, MD

BACKGROUND: Angiotensin II stimulates epithelial Na+ channel (ENaC) by aldosterone-independent mechanism. We now test the effect of angiotensin II on ENaC in the distal convoluted tubule (DCT) and cortical collecting duct (CCD) of wild-type (WT) and kidney-specific mineralocorticoid receptor knockout mice (KS-MR-KO).

METHODS AND RESULTS: We used electrophysiological, immunoblotting and renal-clearance methods to examine the effect of angiotensin II on ENaC in KS-MR-KO and wild-type mice. High K+ intake stimulated ENaC in the late DCT/early connecting tubule (DCT2/CNT) and in the CCD whereas low sodium intake stimulated ENaC in the CCD but not in the DCT2/CNT. The deletion of MR abolished the stimulatory effect of high K+ and low sodium intake on ENaC, partially inhibited ENaC in DCT2/CNT but almost abolished ENaC activity in the CCD. Application of losartan inhibited ENaC only in DCT2/CNT of both wild-type and KS-MR-KO mice but not in the CCD. Angiotensin II infusion for 3 days has a larger stimulatory effect on ENaC in the DCT2/CNT than in the CCD. Three lines of evidence indicate that angiotensin II can stimulate ENaC by MR-independent mechanism: (1) angiotensin II perfusion augmented ENaC expression in KS-MR-KO mice; (2) angiotensin II stimulated ENaC in the DCT2/CNT but to a lesser degree in the CCD in KS-MR-KO mice; (3) angiotensin II infusion augmented benzamil-induced natriuresis, increased the renal K+ excretion and corrected hyperkalemia of KS-MR-KO mice.

CONCLUSIONS: Angiotensin II-induced stimulation of ENaC occurs mainly in the DCT2/CNT and to a lesser degree in the CCD and MR plays a dominant role in determining ENaC activity in the CCD but to a lesser degree in the DCT2/CNT.

Key Words: aldosterone ■ AT1R ■ hyperkalemia ■ hypertension
Angiotensin II and ENaC

CLINICAL PERSPECTIVE

What Is New?
- Angiotensin II stimulates epithelial Na⁺ channel in the distal convoluted tubule by a mineralocorticoid receptor-independent mechanism.
- Type I angiotensin II receptor (AT1R) plays a role in the regulation of epithelial Na⁺ channel activity in the distal convoluted tubule but it is less important in the cortical collecting duct.

What Are the Clinical Implications?
- Our study provides the molecular mechanism by which the inhibition of AT1R causes hyperkalemia in hypertension patients treated with AT1R antagonist.
- Since AT1R activity stimulates K⁺ excretion by a mineralocorticoid receptor-independent mechanism, patients receiving both mineralocorticoid receptor and AT1R antagonists are more vulnerable for developing hyperkalemia.

Nonstandard Abbreviations and Acronyms

| Abbreviation | Definition |
|--------------|------------|
| AngII | angiotensin II |
| AT1R | angiotensin II type 1 receptor |
| CCD | cortical collecting duct |
| CNT | connecting tubule |
| DCT | distal convoluted tubule |
| ENaC | epithelial sodium channel |
| HK | high potassium |
| LS | low Sodium |
| MR | mineralocorticoid receptor |
| ROMK | renal outer medullary K channel |
| SGK1 | serum-glucocorticoid-induced Kinase 1 |

Although both MR and AT1R are expressed in the aldosterone-sensitive distal nephron segments including DCT2 and CCD, the finding that ENaC activity was largely inhibited in the CCD but not significantly affected in the DCT2/CNT of aldosterone synthase-deficient mice suggests that the regulation of ENaC by MR and AT1R may be different between these 2 segments. We now hypothesize that AT1R plays a more important role in stimulating ENaC by an MR-independent mechanism in the DCT2/CNT than in the CCD. The hypothesis is tested by examining the effect of the endogenous aldosterone pathway and AngII pathway on ENaC activity using a renal tubule-specific MR-deficient mouse model.

METHODS

The corresponding author will make the data, methods used in the analysis, and materials used to conduct the research available to any researcher for purposes of reproducing the results or replicating the procedures. The authors also declare that the procedures for animal study were in accordance with institutional guidelines.

Animals and Tubule Preparation

The generation of kidney-specific mineralocorticoid receptor knock-out (KS-MR-KO) mice were described previously, and they were bred at New York Medical College for the experiments. Briefly, mice expressing Pax8-rtTA and tet-on LC-1 transgene were crossed with mr-floxed mice to generate inducible KS-MR-KO. MR deletion was performed in 8-week-old male and/or female mice homozygous for floxed mr-gene and heterozygous for Pax8-rtTA/LC-1 transgene by providing doxycycline (5 mg/mL, 2% sucrose) in the drinking water for 2 weeks. This was followed by at least 2 additional weeks without doxycycline treatment, before performing experiments. Littermate mice of the same age and genetic background drinking 2% sucrose were used as wild-type (WT). Ear DNA was polymerase chain reaction-amplified with the following primers: mr-flox7 (5′-CTGGAGATCTGAACTCCAGGCT) and mr-flox8 (5′-CCTAGAGTTCCTGAGCTGCTGA) and mr-flox10 (5′-TAGAAACACTTCGTAAAGTAGAGCT) yielding a 335 bp product from the floxed mr-gene and a 285 bp product from the wild-type allele; Pax8rtTA forward 5′-CCATGTCTAGACTGGACAAGA-3′ and Pax8rtTA reverse 5′-CAGAAAGTCTTGCCATGACT-3′ which yields a 220 bp product; and LC1-CRE forward 5′-TTTCCCGCAGAAACCTGAGAT-3′ and reverse 5′-TCACCGGCCATACGTTTTTCTT-3′ which yields a 190 bp product. To determine the efficacy of the MR deletion, we used quantitative real-time polymerase chain reaction as described previously.

aldostrone on ENaC is mediated by stimulation of mineralocorticoid receptors (MR). Acute stimulation of MR activates serum-glucocorticoid-induced kinase 1 (SGK1) thereby increasing ENaC activity by inhibiting Nedd4-2-dependent ubiquitination of ENaC. Also, the activation of MR increases the transcription of ENaC in the aldosterone-sensitive distal nephron segments thereby upregulating ENaC expression.

In addition to aldosterone, previous studies have demonstrated that angiotensin II (AngIII) is able to stimulate ENaC activity in the aldosterone-sensitive distal nephron segments by an aldosterone-independent mechanism and that the effect of AngIII is mediated by type I angiotensin II receptor (AT1R) since the inhibition of AT1R abolishes the effect of AngIII on ENaC.

Wu et al Angiotensin II and ENaC
Because KS-MR-KO mice could not tolerate well with high K+ (HK) or low sodium, the mice were fed with control diet (n=9, 0.4% NaCl and 1% KCl), with HK diet (n=6, 5% KCl) for 3 days, or LS diet (n=6, <0.01% NaCl) for 5 days and had free access to water. HK diet (catalog no#TD.110866) and LS diet (catalog no#TD.90228) were purchased from Harlan Laboratory (Madison, WI). To study the effect of AngII infusion on ENaC, we used a no-pressure dose of AngII (200 ng/min per kg BW) for continuous perfusion through a subcutaneously installed osmotic pump (Alzet, Palo Cupertino, CA). We followed the method described previously to prepare the DCT and CCD for the experiments.29–32

Isolation of DCT for the Patch-Clamp Experiments

After mice were euthanized by CO₂ inhalation plus cervical dislocation, the abdomen was opened to expose the left kidney, we perfused the left kidney with 2 mL L-15 medium (Life Technology) containing type 2 collagenase (250 unit/mL). The collagenase-perfused kidney was then removed for further dissection. The renal cortex was separated and cut into small pieces for additional incubation in collagenase-containing L-15 media for 30 to 50 minutes at 37°C. The tissue was then washed 3 times with fresh L-15 medium and transferred to an ice-cold chamber for dissection. The isolated tubules were placed on a small cover glass coated with poly-lysine and the cover glass was placed on a chamber mounted on an inverted microscope. The protocol for using mice was approved by New York Medical College independent animal use committee. We performed the patch-clamp experiments in split-open tubule for studying ENaC activity in the last 100 µm DCT before the transition between the DCT and CNT. Since the diameter of the DCT2 is normally larger than the CNT, this anatomic characterization has been used to determine the end of the DCT or the start of the CNT. Figure 1 is an image of an isolated DCT2/CNT with plain view (A) or with Na-Cl Cotransporter (NCC) staining (B). It is apparent that NCC staining was clearly detected in the DCT. Moreover, the diameter of the CNT directly connected with DCT2 (indicated by an arrow) was smaller than those of the DCT2. However, it was not always obvious to identify the beginning of the CNT since the early portion of the CNT seems to have some morphological characteristic of DCT2. It was likely that some experiments were actually performed in the early CNT. Thus, we have referred that the study was performed in the DCT2/CNT. Also, Figure 1C and 1D show an image of an isolated tubule from DCT1 to CNT with a plain view or with ENaCα staining. It is apparent that ENaCα staining is visible from DCT2 to CNT and that ENaCa staining seems more robust in the DCT2 than in the CNT.

Whole-cell recording

We used an Axon 200A patch-clamp amplifier to record the amiloride-sensitive Na⁺ currents with the perforated whole-cell recording which were low-pass filtered at 1 KHz, digitized by an Axon interface (Digidata 1440A). Data were collected with gap-free protocol and analyzed using the pClamp software system 9.0 (Axon). After forming a high resistance seal (>2 GΩ), the membrane capacitance was monitored until the whole-cell patch configuration was formed. The membrane capacitance (which was used as an index of cell sizes) was also calculated by reading the compensation pF used to offset the membrane capacity induced by forming whole-cell membrane configuration. We have also checked the seal resistances after each experiment to make sure it was stable. ENaC currents were determined by adding amiloride (10 or 100 µmol/L) in the bath solution. Since both doses of amiloride have achieved the same level of inhibition of ENaC, we pooled the results. The pipette solution contained 125 mM/L K-glucinate, 15 mM/L KCl, 2 mM/L MgATP, 1 mM/L EGTA, and 10 mM/L HEPES (pH 7.4), whereas the bath solution contained 130 mM/L Na-glucinate, 10 mM/L NaCl, 5 mM/L KCl, 2 mM/L CaCl₂, 2 mM/L MgCl₂, and 5 mM/L HEPES (pH 7.4). We filled the tip of the pipette first with the above solution without amphotericin B and pipette was then back-filled with the solution containing amphotericin B (20 µg/0.1 mL).

Procedures for Renal Clearance

Animal (n=5 for each group) were anesthetized by 2% to 4% isoflurane through an inhaling mask. The mice were placed on a heated small blanket to maintain body temperature at 37°C. The trachea was cannulated to clear any mucus that may be produced during the experiment. A carotid artery was catheterized with PE10 tubing for blood collection, jugular vein was also cannulated for intravenous infusion. The bladder was exposed and catheterized via a suprapubic incision with a 10-cm piece of PE-10 tubing for urine collections. After completion of surgery, isotonic saline was given intravenously for 4 hours (0.2–0.3 mL/1 hr and total 0.8–1.2 mL 0.9% saline) to replace surgical fluid losses and to maintain hemodynamics. Urine collections started 1 hour after infusion of 0.3 mL saline and a total of 6 collections (every 30 minutes) were performed (2 for controls and 4 for experiments). Benzamil concentration for renal clearance is 5 mg/kg BW. After renal clearance experiment, the mice were euthanized by intravenous somnosal.
Immunoblotting
Whole kidney protein extract was obtained from frozen kidney (n=5 for each group) homogenized in a buffer containing 250 mmol/L sucrose, 50 mmol/L Tris-HCl pH 7.5, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L dithiothreitol (DTT) supplemented with phosphatase and protease inhibitor cocktails (Sigma). Protein (40–60 μg) was separated on 4% to 12% (wt/vol) Tris-Glycine gel (Thermo Fisher Scientific) and transferred to nitrocellulose membrane. The membranes were incubated 1 hour with LI-COR blocking buffer (PBS) and then incubated overnight at 4°C with anti-ENaC-α (Catalog # SPC-403, 1:1000, StressMarq), anti-ENaC-β (catalog# SPC-404, 1:1000, StressMarq) and anti-ENaC-γ subunit (Catalog # SPC-405, 1:1000, StressMarq).

Immunostaining
Isolated DCT/CNT tubules were placed on a small cover glass coated with poly-D-lysine (Sigma-Aldrich), and then were fixed with 4% paraformaldehyde in PBS for 30 minutes. We used 0.2% Triton-X100 in PBS containing 1% BSA to permeabilize tubular cells for 15 minutes. Unspecific binding sites were blocked with 5% donkey serum for 30 minutes at room temperature. Tubules were incubated with rabbit primary antibody of NCC (1:200) or ENaCα (1:500) for overnight at 4°C, washed with PBS, and incubated with An Odyssey infrared imaging system (LI-COR) was used to capture the images at a wavelength of 680 or 800 nmol/L.
Alexa Fluor 488-conjugated donkey anti-rabbit secondary antibody (1:200, Invitrogen) for 1 hour at room temperature.

Materials
Amiloride and benzamil were purchased from Sigma–Aldrich (St. Louis, MO). We have obtained NCC and GAPDH antibodies from StreeMarq and Cell Signaling, respectively.

Statistical Analysis
We used software of SigmaPlot to conduct the statistical analysis. For analyzing the values between 2 groups we used t test and for comparisons of the values within the same group we used paired t test. We used one-way ANOVA for analyzing results of ≥2 groups, and Holm-Sidak test was used as post-hoc analysis. P<0.05 were considered statistically significant. Data are presented as mean±SEM.

RESULTS
We first examined the ENaC activity in the DCT2/CNT and CCD of the wild-type (WT) mice on a control diet (0.4% Na⁺ and 1% K⁺). Figure 2A is a recording of whole-cell Na⁺ currents (at −60 mV) conducted in DCT2/CNT and and in the cortical collecting duct, respectively. Figure 2B is a scatter plot showing each data point and mean value of the amiloride-sensitive Na⁺ currents measured at −60 mV. Figure 2C shows each data point and mean value of the membrane capacity (pF) in the distal convoluted tubule2/connecting tubule and cortical collecting duct, respectively. Figure 2D is a scatter plot showing the normalized epithelial Na⁺ channel density (pA/pF) for the distal convoluted tubule2/connecting tubule and cortical collecting duct. T-test was used for determining the significance between 2 groups. CCD indicates cortical collecting duct; DCT2-CNT, distal convoluted tubule2/connecting tubule.
However, the normalized Na\(^+\) currents density in the DCT2/CNT (10.6±0.5 pA/pF, n=7) was significantly larger than in the CCD (5.0±0.34 pA/pF, n=6). Thus, the results indicate that ENaC density in the DCT2/CNT is higher than in the CCD.

Since aldosterone plays a key role in the regulation of ENaC, we then examined effects of aldosterone on ENaC in the DCT2/CNT by measuring the amiloride-sensitive whole-cell Na\(^+\) current in the mice on a high K\(^+\) diet (5% KCl, HK) for 3 days or a low sodium diet (<0.01% Na\(^+\), LS) for 5 days to stimulate the endogenous aldosterone. Figure 3A is a set of recordings showing amiloride (10 \(\mu\)mol/L)-sensitive Na\(^+\) current measured with whole-cell recording in the DCT2/CNT of the WT mice on control, HK and LS diets, respectively. It is apparent that HK intake increased ENaC current of the DCT2 whereas LS intake did not stimulate ENaC activity in comparison with the control value. Figure 3B is a scatter plot summarizing results of 9 experiments showing the individual data point and the mean value measured at −60 mV. HK intake increased amiloride-sensitive Na\(^+\) currents from 214±6 pA to 388±11 pA but LS intake did not significantly alter ENaC currents (198±4 pA) in comparison with control value. These results were consistent with the previous report that LS diet had no significant effect on ENaC currents in DCT2. To determine whether the stimulatory effect of HK on ENaC in the DCT2/CNT depended on MR, we next examined ENaC currents in the DCT2/
Figure 3C is a set of recordings showing amiloride-sensitive Na⁺ currents measured in the DCT2/CNT of KS-MR-KO mice on control, HK or LS diets. Results of the experiments are summarized in a scatter plot (Figure 3D) showing the mean value and each data point measured at −60 mV. The deletion of MR significantly reduced the amiloride-sensitive Na⁺ currents in the DCT2/CNT of the mice on control diet (134±7 pA, n=9), HK diet (133±12 pA, n=6), and LS diet (135±9 pA, n=6). Moreover, it is apparent that the effect of HK on ENaC was completely absent in KS-MR-KO mice, suggesting that the stimulatory effect of HK on ENaC was dependent on MR presence.

Although the effect of HK on ENaC was absent in the DCT2/CNT of KS-MR-KO mice, the deletion of MR only partially decreased ENaC current. Figure 4A is a bar graph showing the normalized ENaC density in the DCT2/CNT of WT after the consideration of the cell membrane capacity (control, 10.4±0.5 pA/pF; HK 18.9±0.6 pA/pF; LS 9.7±0.4 pA/pF, n=9) and KS-MR-KO mice (control, 6.6±0.5 pA/pF; HK 6.7±0.6 pA/pF; LS 6.6±0.6 pA/pF, n=6–9). The data have suggested that a large portion of ENaC activity in the DCT2/CNT was regulated by MR-independent mechanism.

After showing that MR was only partially responsible for regulating ENaC in the DCT2/CNT, we next examined the ENaC activity in the CCD of WT and KS-MR-KO mice using whole-cell recording. Figure 4B is a scatter plot summarizing results of 6 experiments showing the individual data point and the mean value of ENaC currents measured at −60 mV. HK intake
increased amiloride-sensitive Na⁺ currents from 64±7 pA to 210±23 pA and LS intake further increased ENaC currents (330±28 pA). The deletion of MR not only decreased ENaC currents (11±2 pA, n=6) under control conditions but also abolished the effect of HK (13±2 pA, n=6) and LS (15±2 pA, n=6) on ENaC current in the CCD. Considering the fact that principal cell size was smaller than those in the DCT2/CNT, we presented data in pA/pF to make a comparison with DCT2/CNT. Figure 4C is a bar graph showing that HK intake significantly increased ENaC currents in the CCD from 4.9±0.6 pA/pF (n=6) to 16.2±2 pA/pF (n=6) and that LS intake further increased ENaC currents in the CCD to 25.4±2.6 pA/pF (n=6), a value was significantly larger than ENaC currents of the mice on HK diet. The deletion of MR not only largely eliminated ENaC currents (0.85±0.2 pA/pF, n=6) but also abolished the effect of HK or LS diets on ENaC activity in the CCD (HK, 1.0±0.2 pA/pF; LS, 1.1±0.2 pA/pF, n=6). These results suggest that MR plays a dominant role in determining the ENaC activity in the CCD in comparison with the DCT2/CNT and is indispensable for effects of either HK or LS on ENaC in the CCD.

Because the deletion of MR only partially decreased ENaC currents in the DCT2/CNT, we have speculated whether AT1R may play a role in determining ENaC activity in the DCT2/CNT. Thus, we used the whole-cell

![Figure 5](image)

**Figure 5.** Inhibition of type I angiotensin II receptor decreases epithelial Na⁺ channel in the late distal convoluted tubule/connecting tubule. A bar graph summarizes the results of amiloride-sensitive Na⁺ currents measured at −60 mV in the distal convoluted tubule2/connecting tubule (A) or in the cortical collecting duct (B) of the wild-type mice and kidney-specific mineralocorticoid receptor knockout mice with losartan or vehicle infusion for 3 days. T-test was used for determining the significance between 2 groups. Losartan was infused (4 μg/min per kg BW) by an osmotic pump installed subcutaneously. A scatter plot shows individual values and mean value of amiloride-sensitive Na⁺ currents in the distal convoluted tubule2/connecting tubule (C) and in the cortical collecting duct (D) of the mice treated with angiotensin II for 1 and 3 days, respectively. The experiments were performed with whole-cell recording and the currents were measured at −60 mV. Single asterisk and double asterisks indicate that P value is <0.05 and 0.01, respectively. One-way ANOVA test was used for the statistical analysis. AngII indicates angiotensin II; MR-KO, mineralocorticoid receptor knockout; and WT, wild-type.
recording to examine the ENaC currents in the DCT2/CNT and in the CCD of the WT and KS-MR-KO mice treated with vehicle or losartan (4 μg/min per kg BW) which was infused continuously for 3 days through a subcutaneously installed osmotic pump. The results are summarized in Figure 5A showing that the inhibition of AT1R decreased the ENaC currents in the DCT2/CNT of the WT mice from 10.5±0.5 pA/pF to 7.0±0.5 pA/pA pA (n=5) and in KS-MR-KO mice from 6.6±0.4 to 2.7±0.2 pA/pF (n=5). This finding provides a direct evidence that AT1R plays a role in determining the ENaC activity in the DCT2/CNT under control conditions. In contrast, the inhibition of AT1R had no significant effect on the ENaC currents in the CCD of WT (4.9±0.6 pA/pF versus 4.6±0.3 pA/pF, n=5) and MR-KO mice (0.8±0.2 pA/pF versus 0.77±0.1 pA/pF, n=5) (Figure 5B). These results suggest that AT1R was not essential for maintaining ENaC activity in the CCD under control conditions.

To further examine the role of AngII in regulating ENaC activity, we examined the ENaC activity by measuring amiloride-sensitive Na+ currents in the DCT2/CNT and in the CCD of the mice treated with vehicle or AngII perfusion (200 ng/min per kg, a non-pressor dose) by an osmotic pump for 1 or 3 days. Results of each experiment are summarized in a scatter plot for the DCT2/CNT (Figure 5C) and for the CCD (Figure 5D). Although AngII infusion for 1 day did not significantly change the amiloride-sensitive Na+ currents in the DCT2/CNT (Vehicle, 10.5±0.4 pA, AngII, 10.5±0.6 pA), AngII infusion for 3 days significantly increased ENaC currents (20.1±0.9 pA, n=5). Similar results were observed in the CCD; AngII infusion for 1 day did not affect ENaC currents (4.85±0.6 pA, AngII, 4.6±0.3 pA) (Figure 5B). These results suggest that AT1R was not essential for maintaining ENaC activity in the CCD under control conditions.

Figure 6. Angiotensin II stimulates epithelial Na+ channel in the distal convoluted tubule of kidney-specific mineralocorticoid receptor knockout mice. A, A set of recordings shows the amiloride-sensitive whole-cell Na+ currents in the late distal convoluted tubule2/connecting tubule and in the cortical collecting duct of kidney-specific mineralocorticoid receptor knockout mice in vehicle and angiotensin II infusion for 3 days. Angiotensin II was infused continually through a subcutaneous osmotic pump. The epithelial Na+ channel currents were measured at −60 mV. B, A scatter plot shows mean value and each data point of experiments in which amiloride-sensitive whole-cell Na+ currents were measured at −60 mV in the distal convoluted tubule and the cortical collecting duct of kidney-specific mineralocorticoid receptor knockout mice treated with vehicle or angiotensin II for 1 or 3 days. Single asterisk and double asterisks indicate that P value is <0.05 and 0.01, respectively. One-way ANOVA test was used for the statistical analysis. AngII indicates angiotensin II; CCD, cortical collecting duct; DCT2-CNT, distal convoluted tubule2/connecting tubule; ENaC, epithelial Na+ channel; and KS-MR-KO, kidney-specific mineralocorticoid receptor knockout.
4.6±0.3 pA, n=5). However, AngII infusion for 3 days increased the ENaC current to 9.4±0.8 pA (n=6). After demonstrating that the stimulation of AT1R increased ENaC activity in the DCT2/CNT and the CCD, we next examined whether MR was involved in mediating the effect of AngII on ENaC.

Thus, we next examined ENaC currents in the DCT2/CNT and in the CCD of KS-MR-KO mice treated with vehicle or AngII, respectively. Figure 6A is a set of traces showing amiloride-sensitive whole-cell Na⁺ currents in the DCT2/CNT and in the CCD of KS-MR-KO mice. Figure 6B is a scatter plot summarizing each data point and the mean value of ENaC currents in the DCT2/CNT (left panel) and in the CCD (right panel) of the vehicle-treated and AngII-treated mice. Like WT mice, AngII infusion for 1 day had no significant effect on ENaC in the DCT2 (6.6±0.6 versus 6.73±0.6 pA/pF, n=6) nor in the CCD (0.8±0.15 versus 0.85±0.1 pA/pF, n=6). However, AngII infusion for 3 days caused a larger increase of ENaC currents in the DCT2/CNT (14.2±1 pA/pF, n=6) than in the CCD (2±0.23 pA/pF, n=6), indicating that AngII was able to stimulate ENaC activity in the DCT2/CNT but to a lesser degree in the CCD by an MR-independent mechanism. Since AngII perfusion for 3 days increased ENaC currents in both WT and KS-MR-KO mice, we examined whether AngII stimulated ENaC expression in the mice receiving AngII infusion for 3 days. Figure 7 is a western blot showing that AngII infusion for 3 days increased ENaC expression in WT and KS-MR-KO mice (n=5). From the inspection of Figure 7, it is apparent that the deletion of MR decreased the expression of total ENaCα (80±5% of control value), full-length ENaCγ (70±5% of control value), and cleaved ENaCγ (30±3% of control value). Moreover, infusion of AngII for 3 days modestly but significantly increased the expression of ENaCα (120±5% of the control), robustly increased the expression of ENaCβ (275±15% of the control value), full-length ENaCγ (310±15%) and cleaved ENaCγ (470±30%) in WT mice. Also, AngII infusion also increased the expression of all ENaC subunits in KS-MR-KO mice (ENaCα, 110±5%; ENaCβ, 195±10%; full-length ENaCγ, 160±10%; cleaved ENaCγ, 10±5%).

**Figure 7.** Angiotensin II perfusion stimulates epithelial Na⁺ channel expression.

A western blot shows the expression of epithelial Na⁺ channel subunits in wild-type and the kidney-specific mineralocorticoid receptor knockout mice with or without AngII treatment. Full-length and cleaved epithelial Na⁺ channel-gamma subunits are indicated by an arrow. The normalized band density of epithelial Na⁺ channel expression is summarized in a set of bar graph (right panel). T-test was used for determining the significance between 2 groups. Single asterisk and double asterisks indicate that P value is <0.05 and 0.01, respectively. AngII indicates angiotensin II; ENaC, epithelial Na⁺ channel; MR-KO, mineralocorticoid receptor knockout; and WT, wild-type.
560±30% of the control value). These data have strongly indicated that AngII is able to stimulate ENaC expression by an MR-independent mechanism.

Since AngII infusion increased ENaC currents and expression in KS-MR-KO mice, it is conceivable that AngII should augment the benzamil-induced natriuresis in KS-MR-KO mice treated with AngII. Thus, we used renal clearance experiments to examine the effect of benzamil (5 mg/kg body weight) on urinary Na⁺ excretion (ENa). Figure 8A summarizes results from each individual experiment (5 mice for each group) and Figure 8B is a scatter graph showing the delta value of benzamil-induced net Na⁺ excretion (before and after benzamil). From the inspection of Figure 8A, it is apparent that benzamil-induced natriuresis in KS-MR-KO mice treated with AngII (0.62±0.04 to 2.56±0.16 μEq/min per 100 g BW) was significantly larger than in untreated mice (1.0±0.06 to 1.62±0.06 μEq/min per 100 g BW). Thus, AngII infusion for 3 days is able to stimulate ENaC activity by an MR-independent mechanism. Moreover, AngII infusion significantly decreased the basal level of renal Na⁺ excretion (0.62±0.04 versus 1.0±0.06 μEq/min per 100 g BW), indicating that AngII enhanced renal Na⁺ absorption.

Because AngII stimulates ENaC activity, it is conceivable that AngII should also stimulate renal K⁺ excretion in KS-MR-KO mice. Thus, we have also used the renal clearance method to examine the effect of benzamil on renal K⁺ excretion (EK) in untreated KS-MR-KO mice and the mice treated with AngII infusion for 3 days. Figure 8C is a line graph demonstrating the results of each experiment, the mean values and

---

**Figure 8.** Angiotensin II (AngII) perfusion augments benzamil-sensitive renal Na⁺ excretion and increases renal K⁺ excretion.

A, A line graph summarizes each individual data point and mean value of experiments in which renal clearance was used to examine benzamil (5 mg/kg body weight)-induced renal Na⁺ excretion in the kidney-specific mineralocorticoid receptor knockout mice treated with vehicle (No AngII) and AngII infusion for 3 days. B, A scatter plot shows the difference of net Na⁺ excretion before and after benzamil (delta value) in kidney-specific mineralocorticoid receptor knockout mice treated with vehicle or AngII for 3 days. C, A line graph summarizes each individual data point and mean value of experiments in which renal clearance was used to examine benzamil-induced reduction of renal K⁺ excretion (EK) in kidney-specific mineralocorticoid receptor knockout mice treated with vehicle or AngII infusion for 3 days. D, A scatter plot shows the difference of basal renal K⁺ excretion (EK) before and after benzamil (delta value) in kidney-specific mineralocorticoid receptor knockout mice treated with vehicle or AngII for 3 days. Benzamil concentration for renal clearance: 5 mg/kg BW. Single asterisk and double asterisks indicate that P value is <0.05 and 0.01, respectively. Paired t test was used for analyzing data in (A and C) whereas t test was used for analyzing results in (B and D). AngII indicates angiotensin II; and ENa, Na⁺ excretion.
Wu et al Angiotensin II and ENaC

statistical information from a total of 5 mice for each group. Figure 8D is a scatter plot showing delta values of benzamil-induced net K⁺ excretion (before and after benzamil). The K⁺ excretion under basal (vehicle) conditions was significantly smaller (0.19±0.02 μEq/min per 100 g BW) in untreated mice than in AngII-treated mice (0.42±0.03 μEq/min per 100 g BW). Also, the benzamil-induced net K⁺ excretion in AngII-treated mice (0.31±0.01 μEq/min per 100 g BW) was significantly larger than vehicle-treated mice (0.13±0.01 μEq/min per 100 g BW), suggesting that AngII is able to stimulate the net renal K⁺ excretion in KS-MR-KO mice.

After observing that AngII perfusion for 3 days stimulated ENaC and enhanced renal K⁺ excretion in both WT and KS-MR-KO mice, we have speculated that infusion of AngII should decrease the plasma K⁺ concentration. This possibility has been examined by measuring plasma K⁺ in WT and KS-MR-KO mice treated with AngII for 3 days. Figure 9A is a scatter plot showing each data point and mean value of plasma K⁺ in vehicle or AngII-treated WT mice or KS-MR-KO mice and statistical information is summarized in a table (Figure 9B). AngII infusion for 3 days significantly decreased plasma K⁺ in WT mice from 3.86±0.06 to 3.23±0.06 mmol/L (n=6). While plasma K⁺ in KS-MR-KO mice was significantly higher (4.69±0.14 mmol/L) than in WT mice, KS-MR-KO mice treated with AngII for 3 days decreased plasma K⁺ to 3.60±0.17 mmol/L (n=8), a value was not significantly different from the corresponding WT mice. Thus, data have strongly indicated that AngII is able to stimulate ENaC and renal K⁺ secretion by MR-independent mechanism.

DISCUSSION

Our present study has confirmed the previous reports that AT1R plays a role in stimulating ENaC and in facilitating renal K⁺ secretion by an aldosterone-independent pathway.²⁰,²²–²⁴ However, the major finding of our study is to demonstrate that AT1R plays a more important role in regulating ENaC activity by an MR-independent mechanism in the DCT2/CNT than in the CCD under physiological conditions. This notion is supported by several lines of evidence: (1) The deletion of MR largely abolished ENaC activity in the CCD but only partially blunted ENaC activity in the DCT2/CNT; (2) The inhibition of AT1R with losartan significantly decreased amiloride-sensitive Na⁺ currents in the DCT2/CNT but it had no significant effect on ENaC currents in the CCD under control conditions; (3) Only the combined inhibition of MR and AT1R was able to largely inhibit ENaC activity in the DCT2/CNT; (4) Losartan treatment decreased amiloride-sensitive Na⁺ currents in the DCT2/CNT of KS-MR-KO mice to the same degree as those in WT mice. Thus, data have strongly suggested that MR plays a dominant role in determining ENaC activity in the CCD and that AT1R is constitutively involved in determining the ENaC activity in the DCT2/CNT but it may not be involved in determining the basal ENaC activity in the CCD under control conditions. However, a previous study had reported that losartan treatment further enhanced the spironolactone-induced inhibition of ENaC activity in the CCD of the mice on Na⁺-deficient diet.²² Thus, it is possible that AT1R may play a role in synergizing the effect of aldosterone on ENaC in the CCD during Na⁺ restriction.

The notion that AT1R stimulates ENaC activity in the DCT2/CNT by an MR-independent mechanism is also supported by 2 additional findings. First, AngII infusion (at no pressure dose) for 3 days had a robust stimulatory effect on ENaC in the DCT2/CNT of KS-MR-KO mice. Second, renal clearance experiments have demonstrated that benzamil-sensitive renal Na⁺
Na+ currents in the DCT2/CNT, although it robustly amiloride-sensitive Na+ currents in the DCT2/CNT under control conditions. We speculate that larger be mainly responsible for increasing Na+ absorption in the CCD, ENaC activity in the DCT2/CNT should that the amiloride-sensitive Na+ currents were still ing ENaC activity in the DCT2/CNT whereas only MR is mainly responsible for determining ENaC activity in the CCD. This notion was supported by the finding that the magnitude of the MR-deletion induced inhibition of ENaC was different between the DCT2/CNT and CCD. While ENaC currents were almost absent in the CCD of KS-MR-KO mice, amiloride-sensitive Na+ currents in the DCT2/CNT were only partially decreased, suggesting that MR was only partially responsible for regulating ENaC activity in the DCT2/CNT. The observation that the amiloride-sensitive Na+ currents were still detected in the DCT2/CNT of the KS-MR-KO mice treated with losartan suggests either incomplete inhibition of AT1R or that factors other than MR and AT1R may be also involved in the regulation of ENaC activity in the DCT2/CNT. In this regard, previous studies have shown that vasopressin and insulin/insulin-like-growth factor are involved in regulating ENaC activity. However, AT1R and MR should be 2 major players for determining ENaC activity in the DCT2/CNT under physiological conditions since the remaining ENaC activity in the DCT of KS-MR-KO mice treated with losartan was relatively small.

We have also confirmed previous observations that low Na+ intake did not increase amiloride-sensitive Na+ currents in the DCT2/CNT, although it robustly increased ENaC currents in the CCD. Since increasing dietary K+ intake was able to stimulate ENaC in the DCT2/CNT, it was unlikely that the lack of stimulatory effects of low Na+ intake on ENaC was because of the saturation of MR in the DCT2/CNT. One possibility is that low Na+ intake might selectively increase the ENaC expression/transcription in the DCT2/CNT, whereas HK intake stimulates ENaC equally in the DCT2/CNT and CCD. Further experiments are required to examine the effect of low Na+ intake on ENaC expression/transcription in the DCT2/CNT and in the CCD.

We and others have demonstrated that acute application of AngII activated ENaC in the CCD. However, AngII infusion for 1 day did not significantly increase amiloride-sensitive Na+ currents. In contrast, ENaC currents in the DCT2/CNT and the CCD were significantly increased in the mice treated with AngII for 3 days. It is possible that AngII may stimulate ENaC by a short-term and a long-term mechanism: acute application of AngII-induced stimulation of ENaC was induced by increasing superoxide products, suggesting that the effect of AngII on ENaC may be transient. On the other hand, prolonged AngII application has been shown to increase the expression of all 3 ENaC subunits. Furthermore, our present experiment has demonstrated that AngII-induced stimulation of ENaC was not dependent on MR because AngII infusion was still able to stimulate ENaC expression in KS-MR-KO mice.

We confirmed the previous finding that KS-MR-KO mice had a higher plasma K+ levels than their corresponding WT as the consequence of decreased ENaC activity. However, even in the absence of MR, the mice were able to maintain the plasma K+ concentrations in a relative normal range, suggesting that KS-MR-KO mice were able to excrete K+ by an MR-independent mechanism. A previous study has demonstrated that the deletion of MR activated the renin-angiotensin II system since MR-deficient mice increased plasma renin and angiotensin II concentrations by 50-folds and Loffing et al have reported losartan treatment decreased renal K+ excretion in aldosterone synthase deficient mice. Thus, it is conceivable that the activation of the renin-angiotensin II system may be responsible for preventing severe hyperkalemia in KS-MR-KO mice. This notion is also confirmed by the finding that infusion of AngII for 3 days significantly increased amiloride-sensitive renal K+ excretion thereby completely correcting hyperkalemia in the KS-MR-KO mice and causing hypokalemia in the WT mice. Considering the fact that AngII stimulates ENaC in the DCT2/CNT more than in the CCD, enhancing K+ excretion in the DCT should be mainly responsible for augmenting renal K+ excretion. The finding that AngII perfusion can correct high plasma K+ in KS-MR-KO mice also suggests the possibility that ENaC activity in the DCT2/CNT plays a more important role in mediating ENaC-dependent K+ excretion than in the CCD under physiological conditions. This speculation is also supported
by the previous report that deletion of ENaC in the collecting duct did not affect Na and K homeostasis.28

**Perspectives**

The role of aldosterone-MR in stimulating ENaC activity is well established.2,19,39–41 Also, several studies have demonstrated that acute stimulation of AT1R was able to stimulate ENaC.20,21,24,37 The physiological significance of the present study is to demonstrate that AT1R plays an important role in maintaining ENaC activity in the late DCT2/CNT by an MR-independent mechanism. Moreover, we have provided the evidence that the regulation of ENaC by AngII-AT1R pathway mainly occurs in the DCT2/CNT and to a lesser degree in the CCD. In contrast, MR plays a dominant role in determining ENaC activity in the CCD but to a lesser degree in the DCT2/CNT.

**REFERENCES**

1. Loffing J, Pietri L, Aregerg F, Bloch-Faure M, Ziegler U, Menetton P, Rossier BC, Kaissling B. Differential subcellular localization of ENaC subunits in mouse kidney in response to high- and low-Na diets. Am J Physiol Renal Physiol. 2000;279:F252–F258.
2. Snyder PM. The epithelial Na+ channel: cell surface insertion and retrieval in Na+ homeostasis and hypertension. Endocr Rev. 2002;23:258–275.
3. Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol. 2008;19:1845–1854.
4. Palmer LG, Frindt G. Amloride-sensitive Na channels from the apical membrane of the rat cortical collecting tubule. Proc Natl Acad Sci USA. 1986;83:2767–2770.
5. Nesterov V, Dahlmann A, Krueger BK, Bertog M, Loffing J, Kormbacher C. Aldosterone-dependent and -independent regulation of the epithelial sodium channel (ENaC) in mouse distal nephron. Am J Physiol Renal Physiol. 2012;303:F1289–F1299.
6. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier BC, Lifton RP. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet. 1995;11:76–82.
7. Soundararajan R, Pearce D, Kleyman TR. Role of epithelial sodium channels and their regulators in hypertension. J Biol Chem. 2010;285:30363–30369.
8. Hansson JH, Schild L, Lu Y, Wilson TA, Gautsch I, Shimkets R, Nelson-Williams C, Rossier BC, Lifton RP. A de novo nonsense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci USA. 1995;92:11495–11499.
9. Frindt G, Palmer LG. K+ secretion in the rat kidney: Na+ channel-dependent and -independent mechanisms. Am J Physiol Renal Physiol. 2009;297:F389–F396.
10. Gebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol Renal Physiology. 1998;274:F817–F833.
11. Maslamsani S, Kim GH, Mitchell C, Wade JB, Knepper MA. Aldosterone-mediated regulation of ENaCs, b and g subunit proteins in rat kidney. J Clin Invest. 1999;104:R19–R23.
12. Muller O, Parnova RG, Centeno G, Rossier BC, Firsov D, Horisberger JD. Mineralocorticoid effects in the kidney: correlation between aENaC, GILZ, and Sgk-1 mRNA expression and urinary excretion of Na+ and K+. Am J Physiol. 2003;14:1107–1115.
13. Palmer LG, Antonian L, Frindt G. Regulation of apical K and Na channels and Na/K pumps in rat cortical collecting tubule by dietary K. J Gen Physiol. 1994;104:693–710.
14. Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe N, Kirz W, Warth R, Gregor R, Schutz G. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci USA. 1998;95:9424–9429.
15. Zhou R, Patel SV, Snyder PM, Neddf-2 catalyzes ubiquitination and degradation of cell surface ENaC. J Biol Chem. 2007;282:20207–202012.
16. Kamynina E, Staub O. Concerted action of ENaC, Neddf-2, and Sgk1 in transepithelial Na+ transport. Am J Physiol Renal. 2002;283:F377–F387.
17. Chen SY, Bhargava A, Mastroberardino L, Mejier OC, Wang J, Buse P, Firestone GL, Verrey F, Pearce D. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA. 1999;96:2514–2519.
18. Staub O, Verrey F. Impact of Neddf-4 proteins and serum and glucocorticoid-induced kinases on epithelial Na+ transport in the distal nephron. Am J Physiol. 2005;16:3167–3174.
19. Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension. 1992:19:221–227.
20. Beutler KT, Maslamsani S, Turban S, Nielsen J, Brooks HL, Ageloff S, Fenton RA, Packer RK, Knepper MA. Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension. 2003;41:1143–1150.
21. Sun P, Yue P, Wang WH. Angiotensin II stimulates epithelial sodium channels in the cortical collecting duct of the rat kidney. Am J Physiol Renal Physiol. 2012;302:F679–F687.
22. Mamenko M, Zaika O, Prieto MC, Jensen VB, Doris PA, Navar LG, Pochynuk O. Chronic angiotensin II infusion drives extensive aldosterone-independent epithelial Na+ channel activation. Hypertension. 2013;62:1111–1122.
23. Todkar A, Picard N, Loffing-Cueni D, Sorensen MV, Mihailova M, Nesterov V, Makhanova N, Korbmacher M, Wagner CA, Loffing J. Mechanisms of renal control of potassium homeostasis in complete aldosterone deficiency. J Am Soc Nephrol. 2015;26:425–438.
24. Mamenko M, Zaika O, Ilatovskaya DV, Stavuschenko A, Pochynuk O, Angiotensin II increases activity of the epithelial Na+ channel (ENaC) in distal nephron additively to aldosterone. J Biol Chem. 2012;287:660–671.
25. Wang T, Gebisch G. Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Am J Physiol Renal Physiol. 1996;271:F143–F149.
26. Mujais SK, Kaufmann S, Kaz AI. Angioensin II binding sites in individual nephrons. Am J Physiol. 1986;251:F1111–F1122.
27. Terker AS, Yarbrough B, Ferdaus MZ, Lazelle RA, Ersparmer KJ, Meiermeier NP, Park HJ, McCormick JA, Yang CL, Ellison DH. Direct and indirect mineralocorticoid effects determine distal salt transport. J Am Soc Nephrol. 2016;27:2436–2445.
28. Canonica J, Serci C, Millaard M, Kloesov P, Odermatt A, Koesters R, Loffing-Cueni D, Loffing J, Rossier B, Fratessi S, et al. Adult nephron-specific MR-deficient mice develop a severe renal PHA1 phenotype. PLoS Genet. 2016;12:e1006895.
29. Su XT, Zhang C, Wang L, Gu R, Lin DH, Wang WH. The disruption of KCNJ10 (Kir4.1) stimulates the expression of ENaC in the collecting duct. Am J Physiol Renal Physiol. 2016;310:F985–F993.
30. Zhang C, Wang L, Zhang J, Su XT, Lin DH, Scholl U, Gebisch G, Lifton RF, Wang WH. KCNJ10 determines the expression of the apical Na-Cl channel.
cotransporter (NCC) in the early distal convoluted tubule (DCT1). Proc Natl Acad Sci USA. 2014;111:11864–11869.

31. Wang MX, Cuevas-Gallardo C, Su XT, Wu P, Gao Z-X, Lin DH, McCormick JA, Yang CL, Wang WH, Ellison DH. Potassium (K+) intake modulates NCC activity via the K+ channel. Kir4.1. Kid Int. 2018;93:890–902.

32. Cuevas CA, Su XT, Wang MX, Terker AS, Lin DH, McCormick JA, Yang C-L, Ellison DH, Wang WH. Potassium sensing by renal distal tubules requires Kir4.1. J Am Soc Nephrol. 2017;28:1814–1825.

33. Mironova E, Bugaj V, Kohan DE, Stockand JD. Aldosterone-independent regulation of the epithelial Na+ channel (ENaC) by vasopressin in adrenalectomized mice. Proc Natl Acad Sci USA. 2012;109:10095.

34. Ecelbarger CA, Kim GH, Terris J, Masilamani S, Mitchell C, Reyes I, Verbalis JG, Knepper MA. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol. 2000;279:F46–F53.

35. Ecelbarger CA, Kim GH, Wade JB, Knepper MA. Regulation of the abundance of renal sodium transporters and channels by vasopressin. Exp Neurol. 2001;171:227–234.

36. Ilatovskaya DV, Levchenko V, Brands MW, Pavlov TS, Staruschenko A. Cross-talk between insulin and IGF-1 receptors in the cortical collecting duct principal cells: implication for ENaC-mediated Na+ reabsorption. Am J Physiol Renal Physiol. 2015;308:F713–F719.

37. Peti-Peterdi J, Warnock DG, Beil PD. Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT1 receptors. J Am Soc Nephrol. 2002;13:1131–1135.

38. Rubera I, Loffing J, Palmer LG, Frindt G, Fowler-Jaeger N, Sauter D, Carroll T, McMahon A, Hummler E, Rossier BC. Collecting duct-specific gene inactivation of aENaC in the mouse kidney does not impair sodium and potassium balance. J Clin Invest. 2003;112:554–565.

39. Smith PR, Benos DJ. Epithelial Na+ channels. Annu Rev Physiol. 1991;53:509–530.

40. Pácha J, Frindt G, Antonian L, Silver RB, Palmer LG. Regulation of Na channels of the rat cortical collecting tubule by aldosterone. J Gen Physiol. 1993;102:25–42.

41. Kemendy AE, Kleyman TR, Eaton DC. Aldosterone alters the open probability of amiloride-blockable sodium channels in A6 epithelia. Am J Physiol. 1992;263:C825–C837.